Home › Research › Biomarkers
Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure
Lingler JH, Roberts JS, Kim H, Morris JL, Hu L, Mattos M, McDade E, Lopez OL.. Alzheimer's & dementia (Amsterdam, Netherlands), 2018-05-30
Topic: Amyloid, tau and blood-test diagnosis
Introduction Given mounting calls to disclose biomarker test results to research participants, we explored factors underlying decisions by patients with mild cognitive impairment to receive amyloid imaging results. Methods Prospective, qualitative interviews were conducted with 59 participants (30 = mild cognitive impairment patients, 29 = care partners) from the scan arm of a randomized controlled trial on the effects of amyloid PET results disclosure in an Alzheimer Disease Research Center setting. Results Sixty-three percent of the participants were female, with an average age of 72.9 years, and most had greater than a high school level of education (80%). Primary motivations included: (1) better understanding one's mild cognitive impairment etiology and prognosis to plan ahead, and (2) learning one's brain amyloid status for knowledge's sake, regardless of whether the information is actionable. Most participants demonstrated an adequate understanding of the scan's limitations, yet instances of characterizing amyloid PET as a definitive test for Alzheimer's disease occurred. Mention of potential drawbacks, such as negative psychological outcomes, was minimal, even among care partners. Discussion Findings demonstrate a risk of disproportionate focus on possible benefits of testing among amyloid scan candidates and suggest a need to clearly emphasize the limitations of amyloid PET when counseling cognitively impaired patients and their families before testing. Future research should examine whether minimizing drawbacks at the pre-imaging stage has adverse consequences on results disclosure.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lingler, J. H., Roberts, J. S., Kim, H., Morris, J. L., Hu, L., Mattos, M., et al. (2018). Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure. Alzheimer's & dementia (Amsterdam, Netherlands). https://doi.org/10.1016/j.dadm.2018.05.003
Vancouver
Lingler JH, Roberts JS, Kim H, Morris JL, Hu L, Mattos M, et al. Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure. Alzheimer's & dementia (Amsterdam, Netherlands). 2018. doi:10.1016/j.dadm.2018.05.003. PMID: 30094328.
BibTeX
@article{lingler2018-30094328,
author = {Lingler, J. H. and Roberts, J. S. and Kim, H. and Morris, J. L. and Hu, L. and Mattos, M. and McDade, E. and Lopez, O. L.},
title = {{Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure}},
journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)},
year = {2018},
doi = {10.1016/j.dadm.2018.05.003},
pmid = {30094328},
url = {https://doi.org/10.1016/j.dadm.2018.05.003}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Introduction Given mounting calls to disclose biomarker test results to research participants, we explored factors underlying decisions by patients with mild cognitive impairment to receive amyloid imaging results.
- Methods Prospective, qualitative interviews were conducted with 59 participants (30 = mild cognitive impairment patients, 29 = care partners) from the scan arm of a randomized controlled trial on the effects of amyloid PET results disclosure in an Alzheimer Disease Research Center setting.
- Results Sixty-three percent of the participants were female, with an average age of 72.9 years, and most had greater than a high school level of education (80%).
- Most participants demonstrated an adequate understanding of the scan's limitations, yet instances of characterizing amyloid PET as a definitive test for Alzheimer's disease occurred.
- Future research should examine whether minimizing drawbacks at the pre-imaging stage has adverse consequences on results disclosure.
Why it matters
Interviews with 59 people with mild cognitive impairment and their care partners found that most wanted amyloid PET results mainly to understand prognosis or for knowledge, and few mentioned possible drawbacks. This concerns how people weigh testing decisions and does not treat, cure or prevent Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designrandomized controlled trial
- Participants59
- Evidence strengthHigh
How this study scored 65/100
Published in a leading specialty journal, and it is a randomised controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (Amsterdam, Netherlands)) |
| Journal's citation record | 1 / 4 | Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring: journal h-index 86 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomised controlled trial |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 1 / 4 | 59 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 1 / 2 | Randomised (as stated in the record) |
| Times cited | 3 / 7 | Cited 30 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.0 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 2 / 6 | Cited 1.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 18 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Oscar L. López: h-index 126 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Michigan: institution h-index 2,240 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30094328) |
| Free to read | 2 / 2 | Free to read |
| Total | 65 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.dadm.2018.05.003
- PubMed: 30094328
- Original source →
- Free full text: Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Biomarkers
Also tagged “machine”
835 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.